Laparoscopic associating liver partition and portal vein ligation for staged hepatectomy for colorectal liver metastases: A single-center experience

Table 1 Demographic and tumor characteristics, n (%)

Variable		Overall (n = 15)
Age, years		57 (37-70)
Gender	Male	8 (53.3)
	Female	7 (46.7)
BMI, kg/m2		22.0 (18.6-26.2)
ASA score	2	14 (93.3)
	3	1 (6.7)
Primary tumor
Location	Left	7 (46.7)
	Right	6 (40.0)
	Bilateral	2 (13.3)
Primary tumor resected		11 (73.3)
Liver metastases
Timing of liver metastases	Synchronous	13 (86.7)
	Metachronous	2 (13.3)
Number of tumors	1-5	6 (40.0)
	6-10	4 (26.7)
	11-20	4 (26.7)
	> 20	1 (6.7)
Bilobar disease		8 (53.3)
Max tumor size, mm		2.8 (1.4-6.5)
MHV involvement		7 (46.7)
RAS mutation		9 (60.0)
CEA before ALPPS, ng/mL		9.1 (2.0-179.2)
CRS	2	5 (33.3)
	3	8 (53.3)
	4	2 (13.3)
CAPRA score		2.48 (0.7-4.54)
Extrahepatic metastases		0 (0.0)
Chemotherapy1
Preoperative chemotherapy		14 (93.3)
Cycles of chemotherapy		8 (1-30)
Chemotherapy response	PR	7 (50.0)
	SD	3 (21.4)
	PD	4 (28.6)

¹One patient did not receive preoperative chemotherapy.

BMI: Body mass index; ASA: American Society of Anesthesiologists; MHV: Middle hepatic vein; CEA: Carcinoembryonic antigen; ALPPS: Associated liver partition and portal vein ligation for staged hepatectomy; CRS: Fong’s clinical risk score; CAPRA: Comprehensive associated liver partition and portal vein ligation for staged hepatectomy preoperative risk assessment; PR: Partial response; SD: Stable disease; PD: Progressive disease.